(MedPage Today) — CHICAGO — Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed.
In this 26-week, double-blind trial of 72 adults, 36% who received 1 mg of the…
Source link : https://www.medpagetoday.com/meetingcoverage/ada/116206
Author :
Publish date : 2025-06-23 20:15:00
Copyright for syndicated content belongs to the linked Source.
